PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

rivaroxaban Side Effects

The reactions most often reported to the FDA for rivaroxaban (also sold as Xarelto), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

203,269
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2007 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of rivaroxaban come from 203,269 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 203,269 reports to the FDA Adverse Event Reporting System (FAERS) for rivaroxaban (Xarelto): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

203,269

Reports Mentioning Death

26,830

13.2% of reports — not proof the medicine caused the death

Hospitalizations

102,060

50.2% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

GASTROINTESTINAL HAEMORRHAGE
21,559
HAEMORRHAGE
7,714
DYSPNOEA
7,149
EPISTAXIS
6,698
FATIGUE
6,546
DEATH
6,030
FALL
6,003
PULMONARY EMBOLISM
5,962
ANAEMIA
5,590
CEREBROVASCULAR ACCIDENT
5,543
DIARRHOEA
5,496
DIZZINESS
5,364
NAUSEA
5,235
DEEP VEIN THROMBOSIS
5,152
RECTAL HAEMORRHAGE
5,129
ACUTE KIDNEY INJURY
5,094
THROMBOSIS
4,915
HAEMATURIA
4,908

Who Reports Side Effects

Gender Distribution

Female 91,224 (50%)
Male 91,403 (50%)
Unknown 1,139

Age Distribution

0-17 2,873 (2%)
18-44 8,377 (6%)
45-64 32,734 (23%)
65-74 39,786 (28%)
75+ 56,115 (40%)

Reporting Trend by Year

2007 2025

Reactions in Death Reports

Top reactions reported in 26,830 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 6,020
GASTROINTESTINAL HAEMORRHAGE 4,743
CEREBRAL HAEMORRHAGE 1,638
ACUTE KIDNEY INJURY 1,448
FALL 1,173
HAEMORRHAGE 1,142
UPPER GASTROINTESTINAL HAEMORRHAGE 988
HAEMORRHAGE INTRACRANIAL 986
EPISTAXIS 973
INTERNAL HAEMORRHAGE 964
RECTAL HAEMORRHAGE 916
CEREBROVASCULAR ACCIDENT 853
HAEMORRHAGIC STROKE 851
HAEMATURIA 797
PNEUMONIA 770
ANAEMIA 650
DYSPNOEA 647
RESPIRATORY FAILURE 628
PULMONARY EMBOLISM 616

Reactions in Hospitalization Reports

Top reactions in 102,060 reports where hospitalization was an outcome.

Reaction Reports
GASTROINTESTINAL HAEMORRHAGE 18,375
ACUTE KIDNEY INJURY 4,523
FALL 4,303
UPPER GASTROINTESTINAL HAEMORRHAGE 4,289
ANAEMIA 4,247
DYSPNOEA 4,166
RECTAL HAEMORRHAGE 4,053
EPISTAXIS 3,970
HAEMATURIA 3,456
HAEMORRHAGE 3,227
PULMONARY EMBOLISM 3,212
PNEUMONIA 2,917
CEREBROVASCULAR ACCIDENT 2,873
INTERNAL HAEMORRHAGE 2,780
CEREBRAL HAEMORRHAGE 2,519
ATRIAL FIBRILLATION 2,461
FATIGUE 2,459
ASTHENIA 2,405
NAUSEA 2,403

Compare rivaroxaban vs apixaban →

What the FAERS Data Reveals About rivaroxaban Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 203,269 voluntary reports linked to rivaroxaban and its brand equivalents (Xarelto), spanning 2007 through 2025. Of those, 26,830 (13.2%) listed death as an outcome and 102,060 (50.2%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 50% were female and 50% male; age distribution skews toward 75+, with 56,115 reports in that bracket. The single most reported reaction is gastrointestinal haemorrhage with 21,559 submissions, followed by haemorrhage and dyspnoea.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.